Phaseline

Companies › Fujian Shengdi Pharmaceutical

Fujian Shengdi Pharmaceutical: clinical trials, targets and expected readouts

13 active drug programs in 28 registered trials: 14 Phase 2, 7 Phase 3, 7 Phase 1; Metabolic and endocrine, Cardiovascular, Other, Gastroenterology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
HRS9531 Injection
GLP-1 receptor agonist
GLP1RPhase 3Subjects With Moderate-to-severe OSA and Obesity Who Are on PAP Therapy; Bstructive Sleep Apnea (OSA) and Obesity; Type 2 Diabetes; Obesity …Dec 2026
HRS-5635 Injection–Phase 3Nucleos(t)Ide Analogue-suppressed HBeAg-negative Patients With Chronic Hepatitis B; Chronic Hepatitis BJan 2027
HRS-9057 injection
Radioactively labeled [14C]-HRS-9057
–Phase 2Fluid Retention Caused by Heart Failure; Fluid Retention Due to Heart FailureDec 2026
HRS-9563 Injection–Phase 2Mild to Moderate HypertensionDec 2026
HRS5580 for injection–Phase 2Prevention of Postoperative Nausea and VomitingDec 2026
HRS-7249 Injection
GalNAc-conjugated APOC3-targeted siRNA
APOC3Phase 2Hyperlipidemia; Severe Hypertriglyceridemia With a High Risk of Acute PancreatitisJan 2027
HRS-4729–Phase 2Metabolic Dysfunction-Associated Steatohepatitis (MASH); Overweight/ObesityMar 2027
HRS-5632 Injection–Phase 2Lipoprotein DisorderApr 2027
SHR-1918–Phase 2Severe Hypertriglyceridemia With a High Risk of Acute PancreatitisJun 2027
HRS-7450 Injection–Phase 2Acute Ischemic Stroke–
HRS-4139–Phase 1Psoriasis VulgarisMar 2027
HRS-5817 Injection–Phase 1ObesityApr 2027
HRS-9531 tablet–Phase 1Overweight or Obesity–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06391710HRS9531 InjectionPhase 2Heart Failure With Preserved Ejection FractionCardiovascularJan 2026
NCT07150962HRS-9531 tabletPhase 1Overweight or ObesityMetabolic and endocrineFeb 2026
NCT07318103HRS-9057 injectionPhase 2Fluid Retention Caused by Heart FailureCardiovascularSep 2026
NCT07233070HRS-7450 InjectionPhase 2Acute Ischemic StrokeNeurologySep 2026
NCT06994650HRS9531 InjectionPhase 3Subjects With Moderate-to-severe OSA and Obesity Who Are on PAP TherapyMetabolic and endocrineDec 2026
NCT06974851HRS9531 InjectionPhase 3Bstructive Sleep Apnea (OSA) and ObesityRespiratoryDec 2026
NCT07681479HRS-9057 injectionPhase 1Fluid Retention Due to Heart FailureCardiovascularDec 2026
NCT07709897HRS5580 for injectionPhase 2Prevention of Postoperative Nausea and VomitingOtherDec 2026
NCT07297797HRS-9563 InjectionPhase 2Mild to Moderate HypertensionCardiovascularDec 2026
NCT07540754HRS9531 InjectionPhase 1Diabetes MellitusMetabolic and endocrineJan 2027
NCT07100418HRS-7249 InjectionPhase 2HyperlipidemiaMetabolic and endocrineJan 2027
NCT06425341HRS-5635 InjectionPhase 2Chronic Hepatitis BInfectious diseaseJan 2027
NCT07060456HRS9531 InjectionPhase 3Type 2 DiabetesMetabolic and endocrineFeb 2027
NCT07559136HRS9531 InjectionPhase 1Overweight and ObesityMetabolic and endocrineFeb 2027
NCT07285902HRS9531 InjectionPhase 3ObesityMetabolic and endocrineMar 2027
NCT07807059HRS-4729Phase 1Overweight/ObesityMetabolic and endocrineMar 2027
NCT07802964HRS-4139Phase 1Psoriasis VulgarisImmunologyMar 2027
NCT07185776HRS-5632 InjectionPhase 2Lipoprotein DisorderOtherApr 2027
NCT06934408HRS-5817 InjectionPhase 1ObesityMetabolic and endocrineApr 2027
NCT07599410HRS9531 InjectionPhase 2T2DMMetabolic and endocrineMay 2027
NCT07308392HRS-7249 InjectionPhase 2Severe Hypertriglyceridemia With a High Risk of Acute PancreatitisGastroenterologyJun 2027
NCT07308392SHR-1918Phase 2Severe Hypertriglyceridemia With a High Risk of Acute PancreatitisGastroenterologyJun 2027
NCT07670884HRS9531 InjectionPhase 3Chronic Management of Body WeightOtherOct 2027
NCT07660848HRS9531 InjectionPhase 2Metabolic Dysfunction-Associated Steatohepatitis (MASH)Metabolic and endocrineMar 2028
NCT07660848HRS-4729Phase 2Metabolic Dysfunction-Associated Steatohepatitis (MASH)Metabolic and endocrineMar 2028
NCT07606950HRS-5635 InjectionPhase 3Nucleos(t)Ide Analogue-suppressed HBeAg-negative Patients With Chronic Hepatitis BInfectious diseaseJun 2028
NCT07799688HRS-7249 InjectionPhase 2HyperlipidemiaMetabolic and endocrineOct 2028
NCT07551492HRS9531 InjectionPhase 3Atherosclerotic Cardiovascular DiseaseCardiovascularMay 2031

Targets

GLP1R (1) APOC3 (1)

Companies with the same targets

Eli Lilly Novo Nordisk Roche Hangzhou Sciwind Biosciences Hangzhou Zhongmei Huadong Pharmaceutical Hanmi Pharmaceutical Company AstraZeneca Amgen Regeneron Pharmaceuticals Green Valley (Shanghai) Pharmaceuticals

Companies built like this

Shanghai Minwei Biotechnology Beijing QL Biopharmaceutical Hudson Biotech Shenzhen Salubris Pharmaceuticals Gan & Lee Pharmaceuticals.

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.